N-Zyme Biomedical develops pepsin inhibitor therapies and drug formulations for reflux diseases such as LPR and GERD.
N-Zyme Biomedical Inc. has raised $4.6M in total funding. The most recent round was Series A. The last funding was announced in July 2026.
N-Zyme Biomedical Inc. is headquartered in Milwaukee, United States.
N-Zyme Biomedical develops pepsin inhibitor therapies and drug formulations for reflux diseases such as LPR and GERD.
N-Zyme Biomedical Inc. is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"N-Zyme Biomedical Inc. — Funding & Investors." VCBacked, July 21, 2026, https://www.vcbacked.co/company/n-zyme-biomedical-inc. Accessed August 1, 2026.
VCBacked. (2026). N-Zyme Biomedical Inc. — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/n-zyme-biomedical-inc
{{cite web |title=N-Zyme Biomedical Inc. — Funding & Investors |url=https://www.vcbacked.co/company/n-zyme-biomedical-inc |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated